Prolaio
We're Hiring!
Prolaio Company Growth, Stability & Outlook
What People Are Saying About Prolaio
-
Strong Hiring & Retention: Workforce expansion is evident, with Prolaio reporting 32 new hires in 2025 and continuing to recruit across technical and customer-facing roles. These signals point to organizational scaling backed by ongoing capacity investment.
-
Product Line Growth: Product capabilities advanced with the launch of the OCORO study and an FDA 510(k) clearance for the eVO2peak module in 2025. These developments broaden the digital cardiovascular biomarker portfolio and can support wider clinical use.
-
Strategic Partnerships: The 2025 acquisition by Kardigan ties Prolaio’s cardiovascular data platform directly to active drug-development programs. This connection creates avenues for expanded clinical deployments and operational scale.
